MD-3 Antibody Domain 2 Binding for T Cell Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies targeting ICAM-1, such as enlimomab, either fail to effectively prevent transplantation rejection or induce adverse effects like increased susceptibility to infections and fever, highlighting the need for a more targeted approach that modulates dendritic cell function without general immune suppression.
Innovation Solution
Development of an antibody, MD-3, which binds to domain 2 of human ICAM-1, specifically modulating dendritic cell differentiation and function to induce antigen-specific T cell tolerance, thereby preventing T cell-mediated immune disorders like transplantation rejection and autoimmune diseases while minimizing adverse immunosuppressive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enlimomab (anti-ICAM-1 antibody) is used to block T cell adhesion to endothelial cells, then T cell activation is reduced and graft survival is prolonged, but susceptibility to infections increases and fever adverse effects occur
Solution Approach 1:
The patent applies local quality by targeting a specific domain (domain 2) of the ICAM-1 molecule rather than the entire ICAM-1 structure. The MD-3 antibody binds specifically to domain 2, which is sufficient to modulate dendritic cell function and induce T cell tolerance without completely blocking all ICAM-1 interactions. This localized targeting preserves some ICAM-1 functions while achieving the desired immunomodulatory effect, thereby reducing infection susceptibility compared to broad ICAM-1 blockade.
Solution Approach 2:
The patent segments the ICAM-1 molecule into functional domains and targets only domain 2 with the MD-3 antibody. This segmentation allows selective modulation of dendritic cell differentiation and T cell tolerance induction while leaving other ICAM-1 domains intact to maintain essential immune functions. The segmented approach enables differentiation between tolerogenic effects (achieved) and protective functions (preserved).
2Reliability
If enlimomab blocks ICAM-1/LFA-1 interaction to prevent T cell activation, then acute rejection is reduced, but delayed onset of graft function is not prevented and adverse effects worsen
Solution Approach 1:
The patent uses dendritic cells as an intermediary mechanism to achieve transplantation tolerance. Rather than directly blocking T cell activation through ICAM-1/LFA-1 interference, the MD-3 antibody modulates dendritic cell differentiation and function. These modulated dendritic cells then act as intermediaries to induce antigen-specific T cell tolerance through mechanisms such as anergy induction or regulatory T cell generation. This intermediary approach achieves transplantation success while avoiding the adverse effects of direct T cell blockade.
Solution Approach 2:
The patent inverts the conventional approach by not directly targeting T cells or the ICAM-1/LFA-1 interaction, but rather targeting upstream dendritic cell maturation through ICAM-1 domain 2. By acting on the antigen-presenting cell side rather than the T cell side, the invention achieves tolerance induction through a different mechanistic pathway that avoids the harmful effects of direct T cell suppression.
3Reliability
If MD-3 antibody binds to domain 2 of ICAM-1 to modulate dendritic cell function, then antigen-specific T cell tolerance is induced, but generalized immune suppression is minimized
Solution Approach 1:
The MD-3 antibody exhibits local quality by specifically binding to domain 2 of ICAM-1, which is sufficient to trigger dendritic cell modulation and T cell tolerance induction. This localized binding spares other ICAM-1 domains and their interaction partners, allowing preservation of normal immune functions while achieving targeted tolerogenic effects. The specificity to domain 2 creates a nuanced immunomodulatory profile that distinguishes between tolerogenic and protective functions.
Data Source
Figure 1
Figure 2a~2b
Figure 3A
AI summary
The present invention relates to an antibody binding to the domain 2 of human intercellular adhesion molecules-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and induce antigen-specific T cell tolerance, thereby be effective in the prevention and/or treatment of T cell-mediated immune disorders such as transplantation rejection, graft-versus-host disease, and autoimmune disease. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.